Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (March 2024)
10 slides from Novo Nordisk A/s Class B's investor day presentation, Mar 7, 2024
Slide 1: Rare disease
Novo Nordisk® Rare disease Ludovic Helfgott EVP Rare disease Martin Holst Lange EVP Development 7 MARCH VICTOR DA SILVIA MELCUNAS Victor lives with severe haemophilia A Brazil
Slide 2: Forward-looking statements
2 Rare disease Commercial execution and innovation Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2023 and Form 20-F, which both were filed with the SEC in January 2024
Slide 3: Strategic aspirations 2025
3 Rare disease Commercial execution and innovation Novo Nordisk® Strategic aspirations 2025 • Further raise the innovation-bar for diabetes treatment therapeutic focus • Progress towards zero environmental impact • Develop a leading portfolio of superior treatment Innovation and solutions for obesit
Slide 4: RareD constitutes an attractive opportunity for Novo Nordisk
4 Rare disease Commercial execution and innovation Novo Nordisk® RareD constitutes an attractive opportunity for Novo Nordisk Addressing the unmet needs The Rare disease opportunity for Novo Nordisk Patient burdens1 A strategic portfolio • Reduced life-expectancy play in specialty • Severe co-morbid
Slide 5: Executing on new strategy since 2019 with near-term focus on next generation launches
5 Rare disease Commercial execution and innovation Novo Nordisk® Executing on new strategy since 2019 with near-term focus on next generation launches The Rare disease strategy Focus on succeeding with launches from the core Build on expertise to expand selectively: 2025+ Expand from core • From hae
Slide 6: RareD has carefully selected focus areas within rare blood and rare endocrine disorders
Serve more 6 Rare disease Commercial execution and innovation Novo Nordisk® RareD has carefully selected focus areas within rare blood and rare endocrine disorders The RareD strategy Focus on three rare disease areas Rare bleeding disorders (eg Haemophilia, GT) Strategic focus areas • Persisting unm
Slide 7: Focus to strengthen the rare disease portfolio with internal and external innovation
MLAN – 1 min Find more 7 Rare disease Commercial execution and innovation Novo Nordisk® Focus to strengthen the rare disease portfolio with internal and external innovation Strengthen and progress pipeline Development pipeline 2024 2025 2026 2027 Our key focus areas Somapacitan, SGA, ISS, Turner RED
Slide 8: Phase 3 trial FRONTIER 2 with Mim8 in haemophilia A is expected to read out
MLAN – 1 min Find more 8 Rare disease Commercial execution and innovation Novo Nordisk® Phase 3 trial FRONTIER 2 with Mim8 in haemophilia A is expected to read out during the first half of 2024 FRONTIER 2 trial in >250 adults & adolescents with haemophilia A About Mim8 and the phase 3 trial programm
Slide 9: Focus to move beyond recent supply constraints to leverage launch capabilities
Grow more 9 Rare disease Commercial execution and innovation Novo Nordisk® Focus to move beyond recent supply constraints to leverage launch capabilities Rare disease performance was impacted by supply constraints Market share increases with Refixia® and Sogroya® in the US DKK billion Impacted by su
Slide 10: Closing remarks
Novo Nordisk® Closing remarks Strategy unchanged with focus areas within rare blood and rare endocrine disorders A dedicated Rare disease unit with an early and late-stage pipeline and launch capabilities to support growth Mim8 phase 3 results expected in the first half 2024 VICTOR DA SILVIA MELCUNA